Zura Bio's Latest Market Insights Yet to Be Filed
Zura Bio Announces Participation in June Investor Conferences
Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of senior management will
Express News | Zura Bio Ltd Files for Resale of up to 41.6 Mln Class a Ordinary Shares by the Selling Securityholders - SEC Filing
Zura Bio(ZURA.US) Director Buys US$496K in Common Stock
$Zura Bio(ZURA.US)$ Director Ploos van Amstel Arnout purchased 80,000 shares of common stock on May 17, 2024 at an average price of $6.2 for a total value of $496K.Source: Announcement What is stateme
10-Q/A: Quarterly report (Amendment)
Zura Bio Ltd (ZURA) Q1 2024 Earnings: Financial and Strategic Developments
Zura Bio Is Maintained at Outperform by Oppenheimer
Zura Bio Is Maintained at Outperform by Oppenheimer
Express News | Zura Bio Limited : Oppenheimer Raises Target Price to $21 From $16
Express News | Zura Bio Ltd : Guggenheim Cuts Target Price to $15 From $20
10-Q: Quarterly report
Zura Bio 1Q Loss/Shr 2c >ZURA
Zura Bio 1Q Loss/Shr 2c >ZURA
Zura Bio 1Q Loss $7.75M >ZURA
Zura Bio 1Q Loss $7.75M >ZURA
Express News | Zura Bio Ltd: Projected Cash Runway Extends Support for Operations Through 2027
Express News | Zura Bio Ltd: On Track to Initiate Phase 2 Studies Evaluating Tibulizumab (Zb-106) for Treatment of Systemic Sclerosis (Ssc) in Q4 2024
Express News | Zura Bio Q1 Operating Expenses USD 8.379 Million
Express News | Zura Bio Q1 EPS USD -0.02 Vs. Ibes Estimate USD -0.23
Express News | Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
Zura Bio Initiated at Overweight by Piper Sandler
Zura Bio Initiated at Overweight by Piper Sandler
Express News | Piper Sandler Initiates Coverage On Zura Bio With Overweight Rating, Announces Price Target of $26
Analysts Are Bullish on These Healthcare Stocks: Irhythm Technologies (IRTC), Zura Bio (ZURA)
No Data